Skip to content

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls: a Pilot Randomized Clinical Trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06465602
Acronym
NICE-FIT
Enrollment
60
Registered
2024-06-20
Start date
2024-05-21
Completion date
2025-02-28
Last updated
2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fall, Falls, Frailty, Frailty Syndrome

Keywords

nicotinamide, Nicotinamide supplementation, motor rehabilitation, rehabilitation, exercise, falls, older adults, accidental falls, frail older adults, dietary supplementation

Brief summary

Falls are unplanned events resulting in contact with a lower surface. They are common in older adults, affecting one in three individuals over 65 years old. They have serious consequences, ranging from physical injuries (fractures, traumatic brain injury) to psychological repercussions. Physical training focused on muscle strength, balance, and gait has consistently been shown to prevent falls. However, there are significant challenges in its implementation, such as the need for trained personnel and long intervention times, which are associated with high costs. Therefore, developing strategies to improve the efficiency of physical training programs in older adults is mandatory. The reduced response to physical training in older adults compared to younger individuals is a well-documented phenomenon, reflecting physiological changes associated with aging. Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for cells, mediating energy metabolism and participating in crucial processes such as DNA repair, mitochondrial function, and cell death. As we age, NAD+ levels decrease in various tissues (including the brain and muscle), contributing to the development of aging phenotypes and associated pathologies. Preclinical evidence suggests that increasing NAD+ levels reduces the appearance of aging phenotypes. During physical activity, cellular metabolic pathways that increase the demand for NAD+ to support energy production in mitochondria are activated. This increase in demand is associated with the upregulation of key enzymes involved in NAD+ degradation promoted by exercise. Considering the decrease in cellular levels of this coenzyme associated with aging, it can be hypothesized that NAD+ deficiency may play a significant role in the reduced response of older adults to training programs. Nicotinamide, a water-soluble form of vitamin B3 currently considered a nutritional supplement, is a fundamental precursor for NAD+ synthesis, capable of raising cellular levels of it. It has already been used in clinical practice in the treatment of certain endocrinological and dermatological conditions. This study aims to determine through a randomized clinical trial whether nicotinamide supplementation improves physical performance in older adults at risk of falls undergoing a physical training program.

Detailed description

To test the hypothesis, a randomized pilot clinical trial will be conducted using block allocation, double-blind (patient and evaluator), designed according to the SPIRIT guidelines for drafting a trial protocol. This study involves the implementation of guided home-based physical training by a physiotherapist (2 sessions per week for 4 weeks) combined with supplementation with nicotinamide (1.5 g/day) or placebo depending on the assigned group. Improvement in physical performance will be evaluated using the Short Physical Performance Battery (SPPB), handgrip strength test, quadriceps dynamometry, posturography, and near-infrared spectroscopy (NIRS) of the quadriceps. The RedCap software will be used for randomization and data analysis.

Interventions

DRUGNicotinamide

The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.

DRUGPlacebo

The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.

Sponsors

Centro FONDAP de Gerociencia, Salud mental y Metabolismo (GERO)
CollaboratorUNKNOWN
Center for Advanced Clinical Research (CICA ) - University of Chile
CollaboratorUNKNOWN
University of Chile
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Patients will be assigned to either Nicotinamide or placebo through block allocation. One researcher will be responsible for patient recruitment via telephone and obtaining informed consent. Another researcher will perform patient randomization and drug dispensing. Physiotherapists conducting both the initial and final physical assessments and those conducting rehabilitation sessions will be blinded to the patient's assigned group.

Intervention model description

Pilot randomized clinical trial, block allocation, double-blind

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 65 years or older * Living in the community * Increased risk of falls, defined as: * More than two falls in the last 12 months or * Altered balance test (unable to maintain unipedal stance \> 5 seconds) or * SPPB score less than 10 points

Exclusion criteria

* Known Muscle Disease (dystrophy, myopathy, or similar) * Motor sequelae of stroke * Joint pathology with severe pain preventing strength exercises * Cognitive impairment that renders the informed consent process impossible.

Design outcomes

Primary

MeasureTime frameDescription
Improvement in physical performanceFour weeksAssess the change in total Short Physical Performance Battery (SPPB) performance from baseline to post-4 weeks

Secondary

MeasureTime frameDescription
DynamometryFour weeksChange in dynamometry performance between baseline and post-training
Quadriceps saturationFour weeksChange in quadriceps saturation after a 5-squat test
PosturographyFour weeksChange Center of pressure (COP) between baseline and post-training in posturography
Adverse effectsFour weeksAssessment of adverse effects using a standardized evaluation guideline.
Plasma sample analysisFour weeksNicotinamide leves, Interleukin-13 (IL-13), Interleukin-1(IL-1), Interleukin-6 (IL-6), mixed lineage kinase domain-like (MLKL), receptor interacting protein kinase 3 (RIPK3) and chemokine C-C ligand 2 (CCL-2)
Adherence to medicationFour weeksNicotinamide/placebo usage via self-report survey

Countries

Chile

Contacts

Primary ContactFelipe H Salech Morales, MD PhD
fhsalech@uchile.cl229788546
Backup ContactMaría Isabel Behrens, MD
miobehrens@hcuch.cl229789404

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026